Kite Pharma (Kite Pharma) Change In Working Capital : $92.27 Mil (TTM As of Jun. 2017)

View and export this data going back to 2014. Start your Free Trial

What is Kite Pharma Change In Working Capital?

Kite Pharma's change in working capital for the quarter that ended in Jun. 2017 was $36.69 Mil.

Kite Pharma's change in working capital for the fiscal year that ended in Dec. 2016 was $15.67 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Kite Pharma Change In Working Capital Historical Data

The historical data trend for Kite Pharma's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kite Pharma Change In Working Capital Chart

Kite Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Change In Working Capital

-0.27

0.62

2.96

38.76

15.67

Kite Pharma Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
Change In Working Capital	Get a 7-Day Free Trial														6.92	1.20	9.78	44.61	36.69

Kite Pharma Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $92.27 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Kite Pharma Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Kite Pharma's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kite Pharma (Kite Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kite Pharma Inc (NAS:KITE) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.kitepharma.com

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.

Executives

Jonathan M Peacock	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David Bonderman	director	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Franz B Humer	director	388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Shawn Tomasello	officer: Chief Commercial Officer	C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Farah Champsi	director	ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Helen Susan Kim	officer: EVP, Business Development	3832 BAY CENTER PLACE, HAYWARD CA 94545
Timothy L. Moore	officer: EVP, Technical Operations	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Ran Nussbaum	director	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Cynthia M Butitta	officer: Chief Operating Officer	3165 PORTER DRIVE, PALO ALTO CA 94304
Owen N. Witte	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
David D Chang	officer: EVP, R&D, Chief Medical Off.	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joshua A Kazam	director	689 5TH AVENUE, 12TH FLOOR, NEW YORK NY 10022
Arie Belldegrun	director, officer: Chairman, President and CEO	UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Margo R Roberts	officer: Chief Scientific Officer	2225 COLORADO AVENUE, SANTA MONICA CA 90404

Kite Pharma (Kite Pharma) Headlines

From GuruFocus

Mario Gabelli's Top 5 New Buys for the 3rd Quarter

By Sydnee Gatewood Sydnee Gatewood • 11-03-2017

Andreas Halvorsen Nearly Quadruples Stake in Kite Pharma

By David Goodloe David Goodloe • 10-06-2015

Halvorsen Increases Kite Pharma as Interest in Health Care Remains High

By Holly LaFon Holly LaFon • 03-01-2016

Multiple Companies Achieve Yearly Highs

By yifan900 yifan900 • 10-03-2017

Mario Gabelli Exits Kite Pharma, Trims Time Warner

By Tiziano Frateschi Tiziano Frateschi • 02-07-2018